Co-delivery of Anti-cancer Therapeutics to Treat Cancers Using Nanoparticle Platforms

来源 :2016第九届世界癌症大会 | 被引量 : 0次 | 上传用户:ltiao9600
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  In this talk,I will present the recent research work in our group on the cancer treatment using nanoparticle platform to co-deliver two anti-cancer therapeutics.
其他文献
Diffuse intrinsic pontineglioma (DIPG) is a rare and incurable brain tumor that arises predominately in children and involves the pons,a structure that along with the midbrain and medulla makes up the
会议
Infection of the cervix with an oncogenic form of human papillomavirus (mostly HPV 16 and 18) is the most common cause of cervical cancer.Current screening methods for cervical cancer have several dis
会议
Personalized medicine,in concert with targeted oncologic therapy,has become one of the most active,rapidly advancing,and clinically challenging pursuits in cancer treatment.
会议
Liquid biopsies,examinations of tumor components in body fluids,have shown promise for predicting clinical outcomes.To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA
会议
Translation initiation is an essential biological process.The eukaryotic translation initiation factor (eIF) 3a,the largest subunit of the eIF3 complex,is an important functional element in ribosome e
会议
The ubiquitin-dependent proteasomal degradation of proteins controls signaling and cellular survival and plays an important role in transcriptional regulation.
会议
Detection of somatic mutations from the NSCLC tissue has been routinely practiced to identify eligible patients for the targeted drug therapy.
会议
Resistance to chemotherapy offers limitations to the treatment of breast cancer.This has generated an increased interest in identifying new biomarkers to better predict drug responses among patients.
会议
To retrospectively evaluate the efficacy of HDR (High Dose Rate) brachytherapy (BT) of vaginal intraepithelial neoplasia (VAIN) with a special focus on analysis of toxicity.
会议
A number of large-scale clinical trials have demonstrated that using a combination of oxaliplatin and fluoropyrimidines as an adjuvant chemotherapy for stage Ⅱ/Ⅲ colon cancer improved the prognosis.
会议